Skip to main content
NCBI home page
Virology Journal logoLink to Virology Journal
. 2009 Feb 13;6:21. doi: 10.1186/1743-422X-6-21

Prevalence of HBV and HCV among blood donors in Kosovo

Hajrullah Fejza 1,✉, Skender Telaku 2
PMCID: PMC2649057  PMID: 19216773

Abstract

Hepatitis is disease of the liver caused by the infectious and non-infectious agents.

The aim of study was to analyze the prevalence of HBV and HCV among voluntary blood donors in Kosovo, during 2000–2003.

The data from National Center for Blood Transfusion of Kosovo were collected and analyzed through descriptive and comparative epidemiological method of retrospective study. All samples were tested by ELISA test.

Out of 70348 samples of the blood donors, 3145 were positive. From overall positive samples, 2939 were HBV positive, 192 HCV positive while 14 samples were positive for both viruses.

The HBV prevalence among the blood donors of Kosovo is 4.2%, which range Kosovo to the second zone according to the CDC classification of the geographical spread of the HBV infection.

The HCV prevalence among the blood donors in Kosovo is 0.3%. Compared to the other European countries this level of prevalence is relatively low.

Age group 30–39 years old was presented with 34.8% of cases. The higher number was among the workers, 842 or 26.8%.

Based on the results we can conclude that Kosovo have the similar prevalence for HBV and HCV infections as other South East European countries.

Introduction

Hepatitis is term to describe a nonspecific liver inflammation [1-5]. Until now are known 8 types of hepatitis: A, B, C, D, E, F, G and TT. Hepatitis B and C are similar types of liver infection, which are mostly spread through blood and blood products.

The possibility of hepatitis transmission through blood and blood products were known since 1950 [6-9].

Hepatitis B virus is an AND virus from hepadnaviridae family. Hepatitis C virus is an ARN virus with lipid coat similar to flaviviridae family.

Infected person or asymptomatic carriers with viral hepatitis B and C are only reservoir of infection [8-12].

Researches show as that world prevalence of HBsAg carriers is from 0.1% till 20% with high percentage in tropical countries [5,12].

The prevalence of anti HCV antibody is variety in different world countries with high number reported for Egypt.

Aim of study

The aim of a study was to analyze the prevalence of the HBsAg and anti-HCV antibodies in Kosovo during the period 2000–2003. The possible influence of the various factors on the prevalence was analyzed too. The prevalence was compared with the data available on European and World level.

Material and methodology

Data from databank of the voluntary blood donors of the National Blood Bank in Pristina, as well the data from the databank of the Transfusion Centers in regional Hospitals in Peja, Gjakova, Prizren and Gjilan were used in this study. The analyzed period was from 2000 – 2003.

The method of study was descriptive and comparative in retrospective aspect.

The T – test and Χ2- test were used to analyze the significance of the results.

All samples were tested by ELISA test.

Results

The results of the study showed that from 70348 samples of the blood donated by the blood donors, 3145 were positive. From overall positive samples, 2939 were HBV positive, 192 HCV positive, while in 14 samples both viruses were discovered (Table 1 and Figure 1)

Table 1.

Prevalence of HBV and HCV, Kosovo 2000–2003, by type.

Type of Infection HBV HCV Total
N % N % N %
Mono-infection 2939 99.5 192 93.2 3131 99.6
Bi-infection 14 0.5 14 6.8 14 0.4
Total 2953 100.0 206 100.0 3145 100.0
Open in a new tab

Figure 1.

Figure 1

Open in a new tab

Infected persons with Hepatitis B and C viruses, Kosovo 2000–2003.

Male sex is represented with higher number of infected persons with HBV and HCV. From overall infected persons, 90.3% are male and only 9.7% are female. The same values are shown in infection with HBV whereas a little grow is shown in infection with HCV where female sex is represented with 14.6% (Figure 2)

Figure 2.

Figure 2

Open in a new tab

Infection with HBV and HCV among blood donors in Kosovo, 2000–2003 By type and sex.

The most of infected persons with HBV and HCV belongs to age group from 20–29 years and from 30–39 years.

Higher number is registered in age group from 30–39 years with value of 34.8%, whereas age group from 20–29 years is represented with 33.3%. The less value is shown in age group over 50 year with 4.9%. The average of infected persons is 32.2 year with SD 9.4 (Table 2)

Table 2.

Infection with HBV and HCV among blood donors in Kosovo, by age group and years.

Year Total
Age group 2000 2001 2002 2003 N %
10–19 32 52 126 77 287 9.1
20–29 260 256 322 209 1047 33.3
30–39 262 294 308 232 1096 34.8
40–49 137 113 170 140 560 17.8
50+ 44 25 59 27 155 4.9
Total 735 740 985 685 3145 100.0
Average 33.3 32.0 31.7 32.0 32.2 -
SD 9.3 8.8 10.0 9.4 9.4 -
Open in a new tab

The blood donors which samples were analyzed belong to different occupations. However, the highest number, 842 (26.8%) were workers, followed by pupils with 7.3%. The lowest number was among traders, 3.1%, (Figure 3).

Figure 3.

Figure 3

Open in a new tab

Infection with HBV and HCV among blood donors in Kosovo, 2000–2003 By occupation and years.

Discussion

Infection with HBV and HCV are worldwide significant problem in public health [13-18]. About 5% (300 millions), of world population has chronic infection HBV, which is major factor for developing of chronic liver cirrhosis and carcinoma hepatocelulare [19-23].

According to CDC estimation about 3.9 million people worldwide are infected with HCV, with highest prevalence among age group 30–39 year and about 8000–10 000 death/year from lives disease caused from HCV infection, (CDC, 1998).

The prevalence of HCV in world level can be more than 3%, [1,24-27].

Out of 70348 samples of the blood donors, 3145 were positive. From overall positive samples, 2939 were HBV positive, 192 HCV positive while 14 samples were positive for both viruses.

The HBV prevalence among the blood donors of Kosovo is 4.2%, which range Kosovo to the second zone according to the CDC classification of the geographical spread of the HBV infection.

According to the study done in 1992 among blood donors in Kosovo, the prevalence of HBV was 12, 05%, [21]. We can conclude that after the adequate preventives measures in this period, the prevalence of HBV is decreased significantly.

The prevalence of HBV in dialyses patients in Kosovo is 24.2%, [28]. We think that such highest prevalence is caused because of continually percutane blood exposure.

The HCV prevalence among the blood donors in Kosovo is 0.3%. Compared to the other European countries this level of prevalence is relatively low.

According to the WHO, the world prevalence with HCV is 3.1% [29,30]. The highest prevalence is in Africa, 5.3%, whereas the lowest prevalence is in Europe, 1.03%, [30]. The highest prevalence of HCV between countries in whole the world is in Egypt, 6–28% (mean 22%), [19,31-33].

We can conclude that lower prevalence of HCV in Kosovo is because here are not a lot of people living in high-risk groups for infection with HCV.

The prevalence of HCV among dialyses patients in Kosovo is 38.8%, [28]. This finding can confirm the meaning that long exposure to blood and blood products is with high risk for infection with HCV.

Age group 30–39 years old was presented with 34.8% of cases. The higher number was among the workers, 842 or 26.8%.

Conclusion

• Prevalence of HBV among blood donors in Kosovo is 4.2%.

• Prevalence of HCV among blood donors in Kosovo is 0.3%.

• Based on the results we can conclude that we have the similar prevalence for HBV and HCV infections as other southeast European countries.

Proposition of measures

• To ensure health education activities among population regarding those infections,

• To effort programs and projects which mean the activities with risk group population insisting of them to use condoms and another protection measures during sexual activities and professional care.

• To find sources for completing the lab with best tests such are RIBA and PCR.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

HF carried about data collecting, participated in design of the study and drafted manuscript. ST participated in design of the study and performed the statistical analysis. Both authors read and approved the final manuscript.

Contributor Information

Hajrullah Fejza, Email: drfejzah@gmail.com.

Skender Telaku, Email: skendert@hotmail.com.

References

  1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the US, 1988 through 1994. N England J Med. 1999;341:556–62. doi: 10.1056/NEJM199908193410802. [DOI] [PubMed] [Google Scholar]
  2. Booth JC, O'Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut. 2001;49 doi: 10.1136/gut.49.suppl_1.I1. I-I-21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gerstman B. Epidemiology – kept simple. Second. Chapter 6, 9, 12, 13 & 20. Wiley-Liss, New Jersy; 2003. [Google Scholar]
  4. CDC Updates U.S Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Post exposure Prophylaxis. MMWR. 2001;50 [PubMed] [Google Scholar]
  5. Friss R, Seller ThA. Epidemiology for public health practice. Chapter 12. Jones and Bartlett Publishers, London; 2004. [Google Scholar]
  6. Hillyer CD, Hillyer KL, Strobe FJ, Jeffries LC, Siberstein LE. Handbook of Transfusion Medicine. Chapter 2 and 32. Academic Press, London; 2001. [Google Scholar]
  7. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunology features of hepatic injury and viral persistence. Hepatology. 1999;30:595–601. doi: 10.1002/hep.510300312. [DOI] [PubMed] [Google Scholar]
  8. Mahoney FJ. Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection Clinical Microbiology Review. 1999;12:351–366. doi: 10.1128/cmr.12.2.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Harmening DM. Philadelphia, USA. IV. Vol. 25. 1999. Modern blood banking and Transfusion Practices; pp. 1231–1243. [Google Scholar]
  10. David P, Charles G, David M, Gray JA. Oxford handbook of public health practice. Oxford. 2004;Chapter 1.2 [Google Scholar]
  11. Ebeling F. Epidemiology of the Hepatitis C virus. Vox Sang. 1998;74:143–146. doi: 10.1111/j.1423-0410.1998.tb05412.x. [DOI] [PubMed] [Google Scholar]
  12. Kyi KP, Aye M, Oo KM, Htun Moh Moh, Oo SS, Lwin KO, Win KM. Prevalence of Hepatitis C in Healthy Population and Patients with Liver Ailments in Myanmar. Regional Health Forum WHO South-East Asia Region. 2002;6 [Google Scholar]
  13. Zaller N, Nelson KE, Aladashvili M, Badridze N, del Rio C, Tsertvadze T. Risk factors for Hepatitis C virus infection among blood donors in Georgia. European Journal of Epidemiology, Netherlands. 2004;19:547–553. doi: 10.1023/B:EJEP.0000032352.29173.78. [DOI] [PubMed] [Google Scholar]
  14. Lauer GM, Walker BD. Hepatitis C virus infection. N England J Med. 2001;345:45–52. doi: 10.1056/NEJM200107053450107. [DOI] [PubMed] [Google Scholar]
  15. Nelson K, Wiliams CM, Graham NMH. Infectious Disease Epidemiology. Chapter 19. Jones and Bartlett Publishers, London; 2004. [Google Scholar]
  16. Kimka N, Kingsley LA, Sayah N, Rinaldo CR. Hepatitis C virus infection in a male homosexual cohort: risk factor analysis. Genitourin Med. 1996;72:213–216. doi: 10.1136/sti.72.3.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gordis L. Epidemiology. Third. Elsevier Inc.(USA); 2004. [Google Scholar]
  18. Lok ASF. Chronic hepatitis B. N Engl J Med. 2002;346:1682–3. doi: 10.1056/NEJM200205303462202. [DOI] [PubMed] [Google Scholar]
  19. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann H-WL, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA, for The U.S. Lamivudine Investigator Group Lamivudine as initial treatment for chronic hepatitis B in the United States. N England J Med. 1999;341:1256–1263. doi: 10.1056/NEJM199910213411702. [DOI] [PubMed] [Google Scholar]
  20. Mailliard ME, Gollan JL. Suppressing hepatitis B without resistance – So far, so good. England J Med. 2003;348:848–850. doi: 10.1056/NEJMe020185. [DOI] [PubMed] [Google Scholar]
  21. Ramadani N. PhD thesis. Universitety of Prishtina, Kosovo; 1992. Karakteristikat epidemiologjike dhe serologjike të Hepatitit B në Kosovë. [Google Scholar]
  22. Scotionitis I, Brass CA, Mallet PF. Hepatitis C: Diagnosis and Treatment. J Gen Intern Med. 1995;10:273–282. doi: 10.1007/BF02599887. [DOI] [PubMed] [Google Scholar]
  23. Craig S. Epidemiology of hepatitis B. The pediatric Infectious Disease Journal. 1999;12:433–436. doi: 10.1097/00006454-199305000-00036. [DOI] [PubMed] [Google Scholar]
  24. Carrasco DA, Newman C, Tyring SK. Harrison's Principles of Internal Medicine. 14. Vol. 2. 1998. Treatment of viral hepatitis; pp. 1677–92. [Google Scholar]
  25. Hoofnagle JH. Therapy for acute hepatitis C. N England J Med. 2001;345:1495–1497. doi: 10.1056/NEJM200111153452013. [DOI] [PubMed] [Google Scholar]
  26. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N England J Med. 2002;347:975–982. doi: 10.1056/NEJMoa020047. [DOI] [PubMed] [Google Scholar]
  27. Greenberger NJ. Hepatitis C: More Common than suspected. Clinical focus. 1995. pp. 18–24.
  28. Telaku S, Zekaj S, Avdijaj Xh, Elezi Y, Kuqi Xh, Zylfiu B, Rudhani I, Hasanxhekaj V, Fejza H. Prevalence of hepatitis B and C infection in dialysis patient in Kosova. The Turkish Journal of Gastroenterology. 2003;14 [Google Scholar]
  29. Abdelaal M, Rowbottom D, Zawawi T, Scott T, Gilpin C. Epidemiology of hepatitis C virus. Transfusion. 1994;34:135. doi: 10.1046/j.1537-2995.1994.34294143941.x. [DOI] [PubMed] [Google Scholar]
  30. WHO Hepatitis C global prevalence. Weekly Epidemiological Record. 1999. http://www.who.int/docstore/wer/pdf/1999/wer7449.pdf
  31. Kosgeroglu N, Ayranci U, Vardareli E, Dincer S. Epidemiology & Infection. Vol. 132. Cambridge University Press; 2004. Occupational exposure to hepatitis infection among Turkish nurse; pp. 27–33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med. 2000;132:296–305. doi: 10.7326/0003-4819-132-4-200002150-00008. [DOI] [PubMed] [Google Scholar]
  33. Robertson , Myers G, Howard C, Brettin T, Bukh J, Gaschen B, Gojobori T, Maertens G, Mizokami M, Nainan O, Netesov S, Nishioka K, Shin-i T, Simmonds P, Smith D, Stuyver L, Weiner A. Classification, nomenclature and database development for hepatitis C virus (HCV) and related viruses. Proposal for standardization. Arch Virol. 1998;143:249–503. doi: 10.1007/s007050050479. [DOI] [PubMed] [Google Scholar]

Articles from Virology Journal are provided here courtesy of BMC

RESOURCES